1
|
Weverling F, Roeven M, Nijssen C, Broers AEC, Dovern E, van Rhenen A, Sluis GV, Hazenberg CLE, Balen PV, Kuipers MT, de Vooght KMK, Morsink L, Kuball J, Nur E, de Witte MA. Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data. Blood Adv 2024; 8:1683-1686. [PMID: 38231018 PMCID: PMC11006807 DOI: 10.1182/bloodadvances.2023011190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 11/13/2023] [Accepted: 11/30/2023] [Indexed: 01/18/2024] Open
Affiliation(s)
- Flores Weverling
- Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Mieke Roeven
- Department of Hematology, Radboud University Medical Center; Nijmegen, The Netherlands
| | - Clara Nijssen
- Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Annoek E. C. Broers
- Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Elisabeth Dovern
- Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands
| | - Anna van Rhenen
- Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Geerte van Sluis
- Department of Hematology, Isala Hospital, Zwolle, The Netherlands
| | - Carin L. E. Hazenberg
- Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands
| | - Peter van Balen
- Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
| | - Maria T. Kuipers
- Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands
| | - Karen M. K. de Vooght
- Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Linde Morsink
- Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands
| | - Jürgen Kuball
- Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Erfan Nur
- Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands
| | - Moniek A. de Witte
- Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
| |
Collapse
|
2
|
Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma. Oncol Ther 2022; 10:105-122. [PMID: 35377068 PMCID: PMC9098709 DOI: 10.1007/s40487-022-00195-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 03/10/2022] [Indexed: 11/01/2022] Open
Abstract
Major progress in the treatment of multiple myeloma has been made in the last several years. However, myeloma remains incurable and patients with high-risk cytogenetics or advanced stage disease have an even worsen survival. Only allogeneic transplantation may have curative potential in some patients. However, the high non-relapse mortality and incidence of chronic graft-versus-host disease have raised controversy regarding this procedure. In this review, we will address the role of upfront and delayed allogeneic transplant.
Collapse
|